Go to the Globe and Mail homepage

Jump to main navigationJump to main content


Monday’s analyst upgrades and downgrades Add to ...

Subscribers Only

Inside the Market’s roundup of some of today’s key analyst actions

ProMetic Life Sciences Inc.’s (PLI-T) $53-million equity financing is dilute, but it strengthens its balance sheet, according to Canaccord Genuity analyst Neil Maruoka.

However, citing the dilution resulting from the financing and near-term uncertainty related to its plasminogen treatment, Mr. Maruoka lowered his target for the stock and removed ProMetic for Canaccord’s Canadian Focus List.

Report Typo/Error

Follow on Twitter: @daveleeder


More Related to this Story


Next story




Most popular videos »

More from The Globe and Mail

Most popular